Japanese scientist Tasuku Honjo, a winner of the Nobel Prize in physiology or medicine in 2018, is fighting over patent royalty rate against Ono Pharmaceutical, a Japanese pharmaceutical company.
Reportedly, in 2006, Honjo and Ono entered a license agreement for the patents on PD-1 which was applied to the cancer drug Opdivo (nivolumab). However, in 2011 when Opdivo was along in development, Honjo requested the raise of royalty rate. The negotiation has not proceeded as he expected. So, finally on April 10 2019, Honjo took the step of publishing the background and the outline of the agreement to gain the support of public.
The agreement specifies that Ono has the exclusive right to use the joint patents between Honjo and Ono, and Ono pays a certain of royalties to Honjo. Ono has paid the cumulative amount JPY 2.6 billion (about USD 23.6 million). However, dissatisfied Honjo has not received it and deposited the entire amount with the Legal Affairs Bureau.
Why you should be careful to make your invention joint ownership?
By the way, Honjo decided to make the patent joint ownership, due to budget constraints for patent filing. In Japan, when a joint owner wants to license the patent to a third party, the joint owner is required to obtain the consent from other joint owners. On the other hand, each of joint owners can use the patented invention freely. Therefore, in this case, when Honjo cancels the license agreement, Ono can continue to use the patented inventions, but Honjo cannot license the patents to other companies without Ono’s consent. Therefore, you should be careful to make your inventions joint ownership.
Who should be blamed?
The outline of Honjo’s argument claim is as follows:
- Ono’s explanation on the royalty rate was inaccurate.
- The current royalty rate (less than 1% of sales) is too low.
- He did not have enough time to review the agreement.
- He did not have enough knowledge of patent license agreements.
It is Kyoto University and its licensing organization that are to blame, rather than Ono, in this case. They were in a position to help Honjo negotiate and execute the license agreement with Ono.
Ono made tens-of-billion-of-yen investment in the development of Opdivo when its annual sales was about 100 billion yen. Ono took a big risk. There should have been many projects that were not successful. They need to earn back their investment. If companies are practically forced to change the signed agreement for such reasons above, they may have some anxiety about entering an agreement with Japanese universities.
Honjo established a fund for junior researchers after he received the Nobel Prize. He says he wants to give part of the royalty from Ono to the fund. So, Ono may eventually try to solve this problem by contributing to the fund, considering their reputational risk.
A lesson learned from this case is: What you should have is a good advisor.
Thank you for reading. If you enjoyed this post, I’d appreciate it if you’d help it spread by emailing it to a friend, or sharing it on social media. Thanks!